Author details

Full Name

Jonathan J Keats

Affiliation

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37934799	ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.	Blood Cancer Discov	2024
37485873	CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.		2023
38019104	Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.	Cancer Res Commun	2023
37653344	Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.	Nat Med	2023
37237081	Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.	Nat Cancer	2023
37356470	Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.	Cancer Lett	2023
36670103	Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway.		2023
35134130	Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.	Blood	2022
35653112	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.	Blood Cancer Discov	2022
35637217	Structural variants shape the genomic landscape and clinical outcome of multiple myeloma.	Blood Cancer Journal	2022
36328595	Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing.	Life Sci Alliance	2022
34425325	Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.	Leukemia Research	2021
32296125	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.	Leukemia	2021
33465053	CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.	JCI insight	2021
33731366	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.	Clin Cancer Res	2021
33826614	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.	PLoS One	2021
33649772	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.	Blood	2021
32665698	The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.	Leukemia	2021
33406420	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.	Cell Rep	2021
34788103	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications.	Sci Adv	2021
34504347	Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing.	Nat Biotechnol	2021
34610968	Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.	Cancer Res	2021
31221783	Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myeloma.	Haematologica	2020
32145111	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.	European Journal of Haematology	2020
32143562	CNV Radar: an improved method for somatic copy number alteration characterization in oncology.	BMC Bioinformatics	2020
31595039	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.	Leukemia	2020
32133047	MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21.	Oncotarget	2020
32179748	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias.	Blood Cancer J	2020
32533060	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.	Nat Commun	2020
32921213	Glucocorticoid receptor expression in multiple myeloma patients is a predictor of survival.	Leukemia and Lymphoma	2020
32616499	Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing.	Clinical Cancer Research	2020
33392515	Revealing the impact of structural variants in multiple myeloma.	Blood Cancer Discov	2020
30940637	Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.	Blood advances	2019
31571261	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.	American Journal of Hematology	2019
29967379	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.	Leukemia	2019
31211591	Great Lakes Biorepository Research Network's Annual Biobanking Symposium: A Focus on Precision Medicine.	Biopreserv Biobank	2019
29423797	Whole Genome Library Construction for Next Generation Sequencing.	Methods in Molecular Biology	2018
28642592	Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.	Leukemia	2018
29884741	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.	Blood	2018
30288349	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.	OncoImmunology	2018
30523328	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.	Nat Med	2018
30181174	RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.	Blood	2018
29391353	HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.	Clin Cancer Res	2018
29301755	Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.	Blood	2018
29749396	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.	Leukemia	2018
29209044	Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.	Leukemia	2018
29423798	Whole Exome Library Construction for Next Generation Sequencing.	Methods in Molecular Biology	2018
29166413	Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.	PLoS Genet	2017
28937974	High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.	Blood Cancer J	2017
28369725	RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.	Br J Haematol	2017